Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Trial Details

NCT ID
NCT05624099
Phase
PHASE2
Sponsor
Fujian Cancer Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • camrelizumab
  • Paclitaxel drugs
  • Platinum drug
  • Radiation
Locations (sample)
  • Fuzhou, China|26.06139,119.30611

Key Eligibility Criteria

  • Sign written informed consent and voluntarily participate in this study;
  • Patients with esophageal squamous cell carcinoma confirmed by histopathology and/or immunohistochemistry (8th edition 2017) had UICC/AJCC TNM stage…
  • Survival is expected to exceed 3 months
  • Age 18-75;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →